| Popis: |
Vibhash D Sharma, Kelly E Lyons, Rajesh Pahwa Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA Abstract: Levodopa-induced dyskinesia (LID) is a common motor complication in patients with Parkinson’s disease on chronic levodopa therapy. The management of LID is important as dyskinesia can be disabling and impair quality of life. Currently, there are limited treatment options for the medical management of LID. Amantadine extended-release capsules (Gocovri™) is the first medication that received US Food and Drug Administration approval for the treatment of LID. The following is a review of the pharmacodynamics, efficacy and safety profile, and current state of treatment of amantadine for LID. Keywords: Parkinson’s disease, levodopa-induced dyskinesia, amantadine, amantadine extended-release |
